Central Miami Medical Institute | ClinicalTrials HQ

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
ACP-204 in Adults With Alzheimer's Disease Psychosis	Hallucinations, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, perceptual disorders	Recruiting	Phase 2 / Phase 3	2026-10-05		NCT06159673
Clinical Trial on Agitation in Alzheimer's Dementia	Alzheimer disease, Chemically-Induced Disorders, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, anxiety disorder, brain disorder, cannabis dependence, central nervous system disorder, cognitive disorder, dementia, depressive disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder, substance-related disorder, tauopathy	Active, not recruiting	Phase 2	2026-09-30		NCT05543681
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type	Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, nervous system disorder	Active, not recruiting	Phase 3	2026-09-15		NCT05397639
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)	Bipolar and Related Disorders, bipolar I disorder, bipolar II disorder, bipolar disorder, mood disorder, psychiatric disorder	Enrolling by invitation	Phase 3	2026-09-02		NCT07217860
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)	Bipolar and Related Disorders, bipolar I disorder, bipolar II disorder, bipolar disorder, mood disorder, psychiatric disorder	Recruiting	Phase 3	2026-09-02		NCT07172516